Moneycontrol
Get App
you are here: HomeNewsBusiness
Last Updated : May 06, 2020 03:29 PM IST | Source: PTI

Dr Reddy's Laboratories launches generic hemophilia injection in US

According to IQVIA health data, the desmopressin acetate injection USP brand and generic market had US sales of approximately $20.9 million MAT for the 12 months ended March 2020, it added.

Representative image
Representative image

Dr Reddy's Laboratories on Wednesday said it has launched generic Desmopressin Acetate injection indicated for treatment of hemophilia, in the US. The company has launched Desmopressin Acetate injection USP, 4 mcg/mL single-dose ampules in the US market, Dr Reddy's Laboratories said in a filing to the BSE.

According to IQVIA health data, the desmopressin acetate injection USP brand and generic market had US sales of approximately $20.9 million MAT for the 12 months ended March 2020, it added.

"The launch of desmopressin injection demonstrates a strong, growing collaboration with SunGen Pharma. We look forward to future opportunities with this company," Dr Reddy's Laboratories North America Generics CEO Marc Kikuchi said.

Close

The product is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5 per cent.

"We are pleased to be working with Dr Reddy's for this launch. The launch of desmopressin demonstrates our strong development capabilities. We look forward to collaborating further to bring specialty pharmaceutical drugs to the markets around the world," SunGen Co-CEO Isaac Liu said.

Shares of Dr Reddy's Laboratories were trading at Rs 3,827.90 per scrip on the BSE, down 0.19 percent from the previous close.

Moneycontrol Ready Reckoner
Now that payment deadlines have been relaxed due to COVID-19, the Moneycontrol Ready Reckoner will help keep your date with insurance premiums, tax-saving investments and EMIs, among others.

First Published on May 6, 2020 03:15 pm
Sections
Follow us on